DNA Earnings
Ginkgo Bioworks Holdings Inc
$
11.320
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Ginkgo Bioworks Holdings Inc(DNA) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Ginkgo Bioworks Holdings Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2025Q1 | 2025-05-06 | After Hours | -1.23 | -1.58 | -28.46 | 38.70M | 48.32M | +24.87 | +14.73 | +28.84 |
| FY2024Q4 | 2025-02-25 | After Hours | -1.45 | -1.82 | -25.52 | 44.43M | 43.85M | -1.31 | -11.47 | -21.09 |
| FY2024Q2 | 2024-08-08 | After Hours | -0.08 | -0.11 | +37.50 | 43.04M | 56.21M | +30.60 | -5.59 | -10.84 |
| FY2024Q1 | 2024-05-09 | - | -0.08 | -0.08 | - | 46.04M | 37.94M | -17.58 | +3.02 | -6.05 |
| - | 2023-05-10 | - | -0.09 | -0.08 | +11.11 | - | - | - | -1.46 | -8.76 |
| - | 2023-03-01 | - | -0.30 | -0.04 | +86.67 | - | - | - | -4.76 | -11.56 |
| - | 2022-11-14 | - | -0.25 | -0.40 | -60.00 | - | - | - | -5.96 | -23.16 |
| - | 2022-08-15 | - | -0.05 | -0.41 | -720.00 | - | - | - | -3.86 | -21.49 |
| - | 2022-05-16 | - | -0.04 | -0.05 | -25.00 | - | - | - | -8.65 | -1.88 |
| - | 2022-03-28 | - | -0.05 | -0.01 | +80.00 | - | - | - | +2.19 | +14.75 |
DNA Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Ginkgo Bioworks Holdings Inc reported performance for FY2025Q1, announced on 2025-05-06. The company achieved an EPS of -1.58, compared to analyst estimates of -1.23 by -28.46% . Revenue for the quarter reached 48.32M compared to expectations of 38.70M by 24.87% .
The stock price reacted with a 14.73% one-day change and a 28.84% five-day change following the earnings release. These movements reflect market reaction in Ginkgo Bioworks Holdings Inc growth trajectory and strategic initiatives.
DNA Earnings Forecast
Looking ahead, Ginkgo Bioworks Holdings Inc(DNA) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q2 project quarter revenue of 40.91M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Upward by 3.26%, while EPS estimates have been Revise Downward by -0.44%. For the upcoming , revenue estimates have been adjusted Go Up by 54.22% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Ginkgo Bioworks Holdings Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between DNA's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Upward
+3.26%
In Past 3 Month
Revenue Estimates for Q2 2025
Revise Downward
-0.44%
In Past 3 Month
Stock Price
Go Up
+54.22%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:178.36M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price11.32
DNA Revenue and EPS Performance: A Historical Perspective
Ginkgo Bioworks Holdings Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q1 (2025-05-06,After Hours):
EPS: -1.58 (Actual) vs.-1.23 (Estimate) (-28.46%)
Revenue: 48.32M (Actual) vs. 38.70M (Estimate) (24.87%)
Price Reaction: 14.73%(1-Day), 28.84%(5-Day)
FY2024Q4 (2025-02-25,After Hours):
EPS: -1.82 (Actual) vs.-1.45 (Estimate) (-25.52%)
Revenue: 43.85M (Actual) vs. 44.43M (Estimate) (-1.31%)
Price Reaction: -11.47%(1-Day), -21.09%(5-Day)
FY2024Q2 (2024-08-08,After Hours):
EPS: -0.11 (Actual) vs.-0.08 (Estimate) (37.50%)
Revenue: 56.21M (Actual) vs. 43.04M (Estimate) (30.60%)
Price Reaction: -5.59%(1-Day), -10.84%(5-Day)
Earnings Reaction
The chart below shows how DNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DNA sees a +5.10% change in stock price 10 days leading up to the earnings, and a -8.79% change 10 days following the report. On the earnings day itself, the stock moves by -2.35%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed 14.73% on the day following the earnings release and then changed by 23.88% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Ginkgo Bioworks Holdings Inc (DNA) Q1 2025 Earnings Call Summary
Positive
2025-05-06
The earnings call highlights significant cost reductions, improved cash position, and positive revenue growth in Cell Engineering. Despite challenges in supply chains and government funding, the company's focus on cost management and potential SaaS revenue provides optimism. The Q&A section reveals cautious optimism about government funding and potential SaaS opportunities. The lack of shareholder return plans is a slight negative, but the overall sentiment is positive due to strong financial performance and strategic initiatives.
Ginkgo Bioworks Holdings Inc (DNA) Q1 2025 Earnings Call Summary
Positive
2025-05-06
The earnings call reveals positive financial performance with significant cost reductions, strong revenue growth in cell engineering, and improved EBITDA. The company has a solid cash position and no bank debt. Despite some uncertainties in the Q&A, the ARPA H contract and government projects provide revenue stability. The company is also exploring new opportunities in SaaS and automation, which could drive future growth. The overall sentiment is positive, with potential for stock price appreciation.
Ginkgo Bioworks Holdings Inc (DNA) Q4 2024 Earnings Call Summary
Negative
2025-02-25
The earnings call highlights several concerns: significant revenue decline in Biosecurity, high cash burn, and decreased milestone payments. The lack of shareholder return plans and reliance on government contracts add to uncertainties. Although there's improvement in EBITDA and reduced expenses, guidance remains conservative, and management's unclear responses in the Q&A contribute to a negative sentiment. Despite some positive growth in Cell Engineering revenue, the overall outlook is overshadowed by risks and uncertainties, leading to a likely negative stock price reaction.
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2024 Earnings Call Summary
Negative
2024-11-13
The earnings call reveals challenges such as a 20% decline in cell engineering revenue and high cash burn due to nonrecurring costs, despite improved EBITDA and cash position. The Q&A session highlighted concerns about market competition, regulatory challenges, and unclear future growth potential. The lack of a shareholder return plan and potential biosecurity business risks further weigh negatively. Despite some positive financial adjustments, the overall sentiment is negative, with potential risks outweighing the positives.
People Also Watch
DELL
Dell Technologies Inc
128.960
USD
-1.74%
CVS
CVS Health Corp
61.640
USD
-0.52%
PPC
Pilgrims Pride Corp
45.730
USD
+1.76%
GAME
GameSquare Holdings Inc
1.460
USD
-3.95%
ROKU
Roku Inc
91.690
USD
-1.72%
PYPL
PayPal Holdings Inc
74.820
USD
+0.88%
BNGO
Bionano Genomics Inc
3.490
USD
+1.75%
EXP
Eagle Materials Inc
212.550
USD
-1.19%
F
Ford Motor Co
11.310
USD
+1.34%
GM
General Motors Co
53.210
USD
-0.02%
FAQ
What were the key highlights of DNA’s latest earnings report for FY2025Q1?
DNA reported its FY2025Q1 earnings on 2025-05-06, showcasing a revenue of 48.32M against an estimate of 38.70M, resulting in a 24.87% surprise. The EPS was -1.58, surpassing the expected -1.23 by -28.46% . The stock experienced a 14.73% price change on the earnings day and a 28.84% change over the next five days, reflecting market reactions to the results.
How did DNA’s stock price react after the FY2025Q1 earnings release?
What are the revenue and EPS estimates for DNA for 2025/Q2?
How does DNA’s stock price correlate with earnings forecast revisions?
What should investors expect from DNA’s next earnings report?